ArticleACR open rheumatology2024

Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled Study.

Philip J Mease et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.